Belvarosi Egeszseghaz Kft.
- Address
- lock Available on a paid plan
Cardiovascular Diseases at Belvarosi Egeszseghaz Kft.
The Cardiology Department in Zalaegerszeg, Hungary is running clinical research focused on major cardiovascular diseases, with studies aimed at improving prevention and treatment for people at elevated risk of serious heart and blood vessel events.
- Research on lipoprotein disorders and elevated Lp(a) to test new ways of lowering cardiovascular risk
- Studies in atherosclerotic cardiovascular disease examining whether targeted therapies can reduce heart attack and revascularization events
- Trials in atrial fibrillation looking at safer and more effective options to prevent stroke and systemic embolism
Overall, the site is contributing to efforts that aim to better manage long-term cardiovascular risk and improve outcomes for patients with common and potentially life-threatening heart conditions.
Acute and Recurrent Heart Attack Research
Clinical trials here also address acute myocardial infarction, with a focus on helping people at risk of another cardiac event. These studies are designed to evaluate whether new treatment approaches can improve response when symptoms first appear and support faster, more effective care.
- Investigation of therapies intended to support early treatment during suspected acute myocardial infarction
- Research aimed at reducing the risk of recurrent heart attacks in high-risk patients
- Work centered on improving emergency cardiovascular care and patient outcomes
This line of research reflects a strong interest in time-sensitive heart attack management within the Cardiology Department.
Heart Failure and Inflammation Studies
Another important area at the site involves heart failure, especially HFmrEF and HFpEF with systemic inflammation. These trials are exploring whether new therapies can lower the risk of cardiovascular death and heart failure-related events in patients whose disease remains difficult to control.
- Studies in heart failure with mildly reduced ejection fraction
- Research in heart failure with preserved ejection fraction
- Evaluation of treatments targeting inflammation to improve heart failure outcomes
The research at Belvarosi Egeszseghaz Kft. highlights the growing role of inflammation-focused strategies in cardiovascular care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Arrowhead Pharmaceuticals Inc.3trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Belvarosi Egeszseghaz Kft.
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 3 | Unknown | 2024-11-04 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.